{"filing":{"accession_number":"0001193805-26-000882","cik":"0001280776","ticker":"IMUX","company_name":"IMMUNIC, INC.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"e665616_8k-immunic.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000882/e665616_8k-immunic.htm"},"events":[{"id":14621,"run_id":13024,"accession_number":"0001193805-26-000882","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"IMMUNIC held its annual stockholder meeting and disclosed final voting results, including election of three Class III Directors (Michael Bonney, Thorvald Nagel, and Richard Rudick), approval of an amendment to the 2019 Omnibus Equity Incentive Plan increasing authorized shares by 6,000,000, and ratification of Baker Tilly as independent auditor.","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":12101,"accession_number":"0001193805-26-000882","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan increasing authorized shares by 6,000,000 shares. This is a compensatory arrangement amendment affecting equity grants available to officers and directors, which falls squarely within exec_compensation. The materiality is high given the substantial increase in authorized equity capacity and shareholder approval requirement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:08:28.570448+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12102,"accession_number":"0001193805-26-000882","item_number":"5.07","item_title":"Submission of Matters to","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the final results of stockholder votes at IMMUNIC's annual meeting, including election of three Class III Directors (Michael Bonney, Thorvald Nagel, and Richard Rudick), approval of an amendment to a plan, and ratification of Baker Tilly as independent auditor. The detailed vote tallies and confirmation that all proposals passed are the core disclosure required under Item 5.07 for shareholder vote results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:08:28.570448+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12101,"accession_number":"0001193805-26-000882","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan increasing authorized shares by 6,000,000 shares. This is a compensatory arrangement amendment affecting equity grants available to officers and directors, which falls squarely within exec_compensation. The materiality is high given the substantial increase in authorized equity capacity and shareholder approval requirement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:08:28.570448+00:00","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-06-29"},{"id":12102,"accession_number":"0001193805-26-000882","item_number":"5.07","item_title":"Submission of Matters to","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the final results of stockholder votes at IMMUNIC's annual meeting, including election of three Class III Directors (Michael Bonney, Thorvald Nagel, and Richard Rudick), approval of an amendment to a plan, and ratification of Baker Tilly as independent auditor. The detailed vote tallies and confirmation that all proposals passed are the core disclosure required under Item 5.07 for shareholder vote results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:08:28.570448+00:00","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-06-29"}]}